Document:

EX-10.21

 Exhibit 10.21 

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE EXAGEN INC. HAS DETERMINED THE
INFORMATION (I) IS NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO EXAGEN INC. IF PUBLICLY DISCLOSED. 
 EXCLUSIVE LICENSE
AGREEMENT 
 This Agreement is made and entered into as of the 30th day of September, 2013 (“Effective Date”), by and between
the University of Pittsburgh – Of the Commonwealth System of Higher Education, a non-profit corporation organized and existing under the laws of the Commonwealth of Pennsylvania, with an office at 200 Gardner Steel Conference Center, Thackeray
and O’Hara Streets, Pittsburgh, Pennsylvania 15260 (“University”), and EXAGEN DIAGNOSTICS, INC., a corporation organized and existing under the laws of Delaware, having an office at 800 Bradbury Drive SE Suite 108, Albuquerque, NM
87106 (“Licensee”). 
 WHEREAS, UNIVERSITY is the owner by assignment from the inventors of certain PATENT RIGHTS, entitled
“Diagnosis and Monitoring of Systemic Lupus Erythematosus,” developed by Drs. Susan Manzi and Joseph Ahearn of the UNIVERSITY faculty, consisting of certain patents and patent applications, and the UNIVERSITY has the right to grant
licenses under such PATENT RIGHTS; 
 WHEREAS, the parties have previously entered into a United States-restricted Amended and Restated
License Agreement with respect to the PATENT RIGHTS, effective August 2, 2011 and amended on May 17, 2012, and whereas the parties are contemporaneously entering into a Second Amendment To the Amended and Restated License Agreement with
respect to the PATENT RIGHTS; 
 WHEREAS, University desires to have the PATENT RIGHTS utilized worldwide in the public interest; 

WHEREAS, LICENSEE has represented to UNIVERSITY, to induce UNIVERSITY to enter into this Agreement, that LICENSEE is experienced in the
development, production, manufacture, marketing and sale of products and/or the use of similar products to the LICENSED TECHNOLOGY and that LICENSEE shall commit itself to a thorough, vigorous and diligent program of exploiting the PATENT RIGHTS so
that public utilization results therefrom; and 

 WHEREAS, Licensee desires to obtain a license under the non-US PATENT RIGHTS upon the terms and
conditions hereinafter set forth. 
 NOW, THEREFORE, in consideration of the premises and the mutual covenants contained herein, the parties
hereto, intending to be legally bound, agree as follows: 
 ARTICLE 1 – DEFINITIONS 

For purposes of this Agreement, the following words and phrases shall have the following meanings: 

 

	1.1	 “AFFILIATE” shall mean, with respect to the UNIVERSITY, any clinical or research entity that is
operated or managed as a facility under the UPMC Health System, whether or not owned by UNIVERSITY. 

  

	1.2	 “COMMERCIALLY REASONABLE BEST EFFORTS” shall mean, with respect to the research, development and
commercialization of any product, compound or process, the level of efforts and resources used by [***]. 

  

	1.3	 “LICENSEE” shall mean Exagen Diagnostics, Inc. and all entities at least fifty percent
(50%) owned or controlled by Exagen Diagnostics, Inc. 

  

	1.4	 “LICENSED TECHNOLOGY” shall mean any product or part thereof or service which is:

  

	 	(a)	 Covered in whole or in part by an issued, unexpired or pending claim contained in the PATENT RIGHTS in the
country in which any such product or part thereof is made, used or sold or in which any such service is used or sold; or 

  

	 	(b)	 Manufactured by using a process or is employed to practice a process which is covered in whole or in part by an
issued, unexpired claim or a pending claim contained in the PATENT RIGHTS in the country in which any such process that is included in the SLE FIELD or the MONITORING OF ORGAN 

  

	***	 Certain Confidential Information Omitted 

 
 2 

	 	
TRANSPLANTATION & ORGAN REJECTION FIELD is used or in which such product or part thereof or service is used or sold. 

 

	1.5	 “NON-COMMERCIAL EDUCATION AND RESEARCH PURPOSES” shall mean use of PATENT RIGHTS (including
distribution of biological materials covered by the PATENT RIGHTS) for academic research or other not-for-profit scholarly purposes which are undertaken at a nonprofit or governmental institution that does not use the PATENT RIGHTS in the production
or manufacture of products for sale or the performance of services for a fee. 

  

	1.6	 “NON-ROYALTY SUBLICENSE INCOME” shall mean [***] pursuant to any sublicense granted pursuant to
Section 2.3 hereunder, provided however, that NON ROYALTY SUBLICENSE INCOME does not include [***]. 

  

	1.7	 “PATENT RIGHTS” shall mean UNIVERSITY intellectual property described below and assigned to the
UNIVERSITY: 

  

	 	(a)	 The foreign patents and/or patent applications listed in Exhibit A; 

 

	 	(b)	 Foreign patents issued from the applications listed in Exhibit A and from divisionals and continuations and
continuations in part of these applications; and 

  

	 	(c)	 Claims of foreign continuation in part and divisional applications, and of the resulting patents, which are
directed to subject matter specifically described in the foreign applications listed in Exhibit A. 

  

	***	 Certain Confidential Information Omitted 

 
 3 

	1.8	 “NET SALES” shall mean gross invoice price actually charged by LICENSEE or its Sublicensee to third
parties for LICENSED TECHNOLOGY and services or testing using the LICENSED TECHNOLOGY and services, less the following deductions where they are factually applicable and are not already reflected in the gross invoice price: 

 

	 	(a)	 Actual cost of freight, shipping and insurance charges or freight absorption, separately stated in such
invoice; 

  

	 	(b)	 Actual trade, quantity or cash discounts actually allowed, to include discounts to managed care organizations,
so long as such discounts: (i) are in amounts customary in the trade, and (ii) do not violate federal state laws or regulations; 

  

	 	(c)	 Actual credits and allowances granted for product returns, rejection for damages and recalls;

  

	 	(d)	 Rebates paid or credited to managed care organizations and governmental agencies with respect to Medicaid,
Medicare or similar state and federal government programs; and 

  

	 	(e)	 Sales taxes, tariff duties and/or use taxes actually paid and separately stated on each invoice.

  

	1.9	 “SLE FIELD” shall mean any and all applications of the Patent Rights in Systemic Lupus Erythematosus.

  

	1.10	 “TERRITORY” shall mean worldwide, with the exception of the United States. 

 

	1.11	 “MONITORING OF ORGAN TRANSPLANTATION & ORGAN REJECTION FIELD” shall mean any and all
applications of the Patent Rights in Monitoring of Organ Transplantation & Organ Rejection. 

 ARTICLE 2 –
GRANT 
  

	2.1	 Subject to the terms and conditions of this Agreement, UNIVERSITY hereby grants to LICENSEE, to the extent it
may lawfully do so, the right and exclusive license in the 

  
 4 

	 	
TERRITORY to make, have made, use, offer for sale, import and sell the LICENSED TECHNOLOGY in the SLE FIELD and the MONITORING OF ORGAN TRANSPLANTATION & ORGAN REJECTION FIELD and to
practice under the PATENT RIGHTS in the SLE FIELD and the MONITORING OF ORGAN TRANSPLANTATION & ORGAN REJECTION FIELD to the end of the term for which the PATENT RIGHTS are granted, unless this Agreement is terminated as provided herein.
UNIVERSITY reserves the royalty-free, nonexclusive right to practice under the PATENT RIGHTS for NON-COMMERCIAL EDUCATION AND RESEARCH PURPOSES and to use the LICENSED TECHNOLOGY for NON-COMMERCIAL EDUCATION AND RESEARCH PURPOSES. 

 

	2.2	 The license granted hereby is subject to the rights of the United States government, if any, as set forth in 35
U.S.C. §200, et seq. Pursuant to this law, the United States government may have acquired a nonexclusive, nontransferable, paid up license to practice or have practiced for or on behalf of the United States the inventions described in the
PATENT RIGHTS throughout the world. Pursuant to 35 U.S.C. §200, et seq. LICENSED TECHNOLOGY produced for sale in the United States shall be substantially manufactured in the United States (unless a waiver under 35 U.S.C. §204 is granted by
the appropriate United States government agencies). 

  

	2.3	 LICENSEE shall have the right to enter into sublicensing arrangements (without the right to further sublicense)
for the rights, privileges and licenses granted hereunder. Prior written approval of each sublicensee by UNIVERSITY, which approval shall not be unreasonably withheld or delayed, will be required for all sublicensees except in such cases where the
sublicensee: (1) has at least one FDA approved medical diagnostic test currently on the market: and (2) has yearly revenues from the commercial sale of diagnostic products in excess of [***] dollars ($[***]). Upon termination of this
Agreement, rights of any sublicensee granted by Licensee pursuant to this Section 2.3 shall survive such termination at the written request of such sublicensees provided to UNIVERSITY, provided that the action or inaction of such sublicensee
was not the cause of such termination. 

  

	***	 Certain Confidential Information Omitted 

 
 5 

	2.4	 LICENSEE agrees that any sublicense granted by it shall provide that the obligations to UNIVERSITY of Articles
2, 7, 8, 9, 10, and 13 of this Agreement shall be binding upon the sublicensee as if it were party to this Agreement. Each sublicense granted by LICENSEE pursuant to this Agreement shall include an audit right by UNIVERSITY of sublicensee of the
same scope as provided in Section 5.2 with respect to LICENSEE. 

  

	2.5	 LICENSEE agrees to forward to UNIVERSITY a copy of any and all sublicense agreements promptly upon execution
thereof, but in no event later than thirty (30) days after each such sublicense agreement has been executed by both parties thereto. 

  

	2.6	 The license granted hereunder shall not be construed to confer any rights upon LICENSEE by implication,
estoppel or otherwise as to any technology other than PATENT RIGHTS. 

 ARTICLE 3 – DUE DILIGENCE 

 

	3.1	 LICENSEE shall use its commercially reasonable best efforts to bring the LICENSED TECHNOLOGY to market outside
the United States as soon as practicable, consistent with sound and reasonable business practice and judgment, and to continue active, diligent marketing efforts outside the United States for the LICENSED TECHNOLOGY throughout the term of this
Agreement. 

  

	3.2	 In addition, LICENSEE shall adhere to each of the following milestones: 

 

	 	(a)	 Within thirty (30) months from the Effective Date of this Agreement, execute a commercial partnership
agreement with a third party, or be acquired by a third party, for the purpose of commercialization of the LICENSED TECHNOLOGY outside the United States; and 

  

	 	(b)	 Within fifty-four (54) months from the Effective Date of a commercial partnership agreement with a third
party, or an acquisition by a third party, achieve first commercial sale of LICENSED TECHNOLOGY outside of the United States. 

  

	3.3	 LICENSEE’s failure to perform in accordance with Section 3.1 or to fulfill on a timely basis anyone
of the milestones set forth in Section 3.2 hereof shall be grounds for 

  
 6 

	 	
UNIVERSITY to terminate this Agreement pursuant to Section 10.2(a); except that for a single time, if a milestone in Section 3.2 has not been completed within the time frame allotted
through no fault of LICENSEE and following the best efforts of LICENSEE to meet such milestone, LICENSEE may, on a one-time basis, notify the UNIVERSITY in writing that it desires a single six (6) month extension to meet such milestone and
LICENSEE shall be deemed to have fulfilled the milestone requirement if LICENSEE makes a penalty payment of [***] dollars ($[***]) with both notice and penalty payment to be received by the UNIVERSITY within ten days of the applicable milestone
achievement date. In such case the LICENSEE and UNIVERSITY shall negotiate a new time for attainment of such missed milestone (not to exceed six months) and subsequent timeframes relying upon the meeting of previous milestones may also be adjusted.
If LICENSEE fails to meet any revised milestone including first missed milestone, UNIVERSITY may terminate the License and upon termination all rights and interest to the PATENT RIGHTS and any other rights granted by UNIVERSITY shall revert to
UNIVERSITY. 

  

	3.4	 LICENSEE shall notify UNIVERSITY in writing of the achievement of each milestone in Section 3.2 within
thirty (30) days upon the achievement of the respective milestone. 

 ARTICLE 4 – LICENSE CONSIDERATION

  

	4.1	 In consideration of the rights, privileges and license granted by UNIVERSITY hereunder, LICENSEE shall pay
royalties and other monetary consideration as follows: 

  

	 	(a)	 Initial license fee, nonrefundable and noncreditable against royalties, of [***] Dollars ($[***]) due
immediately and payable within ten (10) business days from the Effective Date of this Agreement; 

  

	 	(b)	 Royalties in an amount equal to [***] Percent ([***]%) of NET SALES of the LICENSED TECHNOLOGY per calendar
quarter and royalties in an amount equal to [***] Percent ([***]%) of sublicensee NET SALES per calendar quarter; 

  

	 	(c)	 A share of NON-ROYALTY SUBLICENSE INCOME of [***] Percent ([***]%). 

  

	***	 Certain Confidential Information Omitted 

 
 7 

	4.2	 In the event that it should prove necessary for LICENSEE to license intellectual property rights owned by a
third party in order to practice the LICENSED TECHNOLOGY in the SLE FIELD or the MONITORING OF ORGAN TRANSPLANTATION & ORGAN REJECTION FIELD in order to avoid infringing the patent or other intellectual property rights of such third party,
then LICENSEE shall be entitled to a credit of such third party royalties against royalties due to UNIVERSITY under Section 4.1(b) provided that (i) in no event shall the royalty rate applicable to NET SALES in the SLE FIELD or the
MONITORING OF ORGAN TRANSPLANTATION & ORGAN REJECTION FIELD be less than [***] percent ([***]%) and (ii) in no event shall the royalty rate applicable to NET SALES in the SLE FIELD or the MONITORING OF ORGAN TRANSPLANTATION &
ORGAN REJECTION FIELD from a sub-Licensee be less than [***] percent ([***]%). 

  

	4.3	 All payments pursuant to this Agreement may be made by check or by wire transfer (along with applicable wire
transfer, transaction, and/or foreign translation fees) in United States dollars without deduction or exchange, collection or other charges and directed to the address or, in the case of wire transfer, to the bank, set forth in Article 11. Royalty
payments pursuant to Section 4.1(b) hereof shall be due within sixty (60) days after each March 31, June 30, September 30 and December 31. NON-ROYALTY SUBLICENSE INCOME payments pursuant to Section 4.1(c)
hereof shall be paid within thirty (30) days after receipt of payment by LICENSEE from sublicense. Payments under Section 4.1(b) are payable on a country by country basis only in those countries in which there are PATENT RIGHTS with
respect to the applicable LICENSED TECHNOLOGY. 

  

	4.4	 Taxes imposed by any foreign or United States governmental agency on any payments to be made to UNIVERSITY by
LICENSEE shall be paid by LICENSEE without deduction from any payment due to UNIVERSITY hereunder. 

  

	4.5	 The balance of any payments pursuant to this Agreement, including those specified in Section 6.2, which
are overdue shall bear interest, compounded monthly, calculated from the due date until payment is received at the rate of five percent (5%) per annum, or the prime rate (as quoted by The Wall Street Journal) plus two percent (2%), whichever is

  

	***	 Certain Confidential Information Omitted 

 
 8 

	 	
higher. Payment of such interest by LICENSEE shall not negate or waive the right of UNIVERSITY to seek any other remedy, legal or equitable, to which it may be entitled because of the delinquency
of any payment, including, but not limited to, termination of this Agreement as set forth in Article 10. Licensee shall reimburse University for any costs and expenses incurred in connection with collecting any overdue balance of payments with
respect to Licensee’s payment and reimbursement obligations under this Agreement, including the costs of engaging counsel or a collection agency for such purpose. 

 

	4.6	 LICENSEE shall sell products and/or services resulting from LICENSED TECHNOLOGY to UNIVERSITY and its
AFFILIATES upon request at such price(s) and on such terms and conditions as such products and/or services are made available to LICENSEE’S most favored customer. 

ARTICLE 5 – REPORTS AND AUDIT 
  

	5.1	 Within sixty (60) days after each March 31, June 30, September 30 and
December 31 of each year during the term of this Agreement beginning in the year of the first commercial sale of LICENSED TECHNOLOGY, LICENSEE shall deliver to UNIVERSITY true, accurate and detailed reports of the following information in a
form as illustrated in Exhibit B: 

  

	 	(a)	 Number of product and service NET SALES for LICENSEE and all sublicensees; 

 

	 	(b)	 Total billings and receivables for all such products and services; 

 

	 	(c)	 Deductions set forth in Section 1.8, each stated separately; 

 

	 	(d)	 Total royalties due; 

 

	 	(e)	 Name and addresses of sublicensees; and 

 

	 	(f)	 Total NON-ROYALTY SUBLICENSE INCOME received during such calendar quarter and total amount of payment due
pursuant to Section 4.1(c). 

  
 9 

	5.2	 LICENSEE shall keep full, true and accurate books of account, in accordance with generally accepted accounting
principles, containing all information that may be necessary for the purpose of showing the amounts payable to UNIVERSITY hereunder. Such books of account shall be kept at LICENSEE’S principal place of business. Such books of account shall be
open at all reasonable times for [***] years following the end of the calendar year to which they pertain, and for [***] years after the expiration or termination of this Agreement, for inspection by UNIVERSITY or its agents for the purpose of
verifying LICENSEE’S royalty statement or compliance in other respects with this Agreement. The fees and expenses of UNIVERSITY’S representatives shall be borne by UNIVERSITY; however, if an error of more than [***] percent ([***]%) of the
total payments due or owing for any year is discovered, then LICENSEE shall bear UNIVERSITY’S fees and expenses. 

  

	5.3	 No later than ninety (90) days after December 31 of each calendar year during the term of this
Agreement, LICENSEE shall provide to UNIVERSITY a written annual progress report, as illustrated in Exhibit C, describing LICENSEE’S progress on research and development, regulatory approvals, manufacturing, sublicensing, marketing and sales
during the preceding twelve-month period ending December 31. 

  

	5.4	 Notwithstanding the above, UNIVERSITY shall have the right, on an annual basis during the term of this
Agreement to inspect technical and other information from LICENSEE sufficient to evidence whether and to what extent LICENSEE is: (a) practicing the PATENT RIGHTS; and (b) meeting its diligence obligations under Article 3, above.

  

	5.5	 LICENSEE shall report to the UNIVERSITY the date of the first commercial sale of a LICENSED TECHNOLOGY within
sixty (60) days of occurrence in each country. 

 ARTICLE 6 – PATENT PROSECUTION 

 

	6.1	 UNIVERSITY has or shall apply for and seek prompt issuance of and maintain during the term of this Agreement
the PATENT RIGHTS in such foreign countries as may be designated by LICENSEE in a written notice to UNIVERSITY within a reasonable time in advance of the required foreign filing dates. LICENSEE shall have the opportunity to

  

	***	 Certain Confidential Information Omitted 

 
 10 

	 	
advise and cooperate with UNIVERSITY in the prosecution, filing and maintenance of such patents. If UNIVERSITY decides to abandon the preparation, filing, prosecution or maintenance of any patent
or patent application covered by the PATENT RIGHTS, then UNIVERSITY shall provide written notice to LICENSEE, and LICENSEE shall have the right at its sole expense to assume control of the preparation, filing, prosecution and maintenance of such
patent application or patent. If LICENSEE no longer wishes to support the prosecution or maintenance of any patent or patent application covered by the PATENT RIGHTS, then LICENSEE shall provide written notice to UNIVERSITY, and LICENSEE shall not
be responsible for such corresponding patent expenses that are incurred subsequent to the date of receipt by UNIVERSITY of such written notice by LICENSEE; such returned patent or patent application shall be excluded from the PATENT RIGHTS. Licensee
shall notify UNIVERSITY immediately if, at any time during the term of this Agreement, LICENSEE or any of its sublicensees does not qualify as a “Small Entity” as provided by the United States Patent and Trademark Office.

  

	6.2	 All fees and costs, including attorneys’ fees, relating to the filing, prosecution, maintenance, and post
grant proceedings relating to the PATENT RIGHTS shall be the responsibility of LICENSEE, whether incurred prior to or after the Effective Date. LICENSEE shall not be required to reimburse the UNIVERSITY for any fees under this section that have been
paid to the UNIVERSITY by prior licensees or any other third party. Fees and costs incurred shall be paid by LICENSEE within thirty (30) days after receipt of UNIVERSITY’S invoice therefor. Additionally, Licensee shall be liable to
UNIVERSITY for all of UNIVERSITY’S out-of-pocket filing, prosecution, and maintenance costs (including all attorneys’ fees and costs), for any and all patent prosecution and maintenance actions that will be taken by patent counsel after
the term of this Agreement but in response to any instructions that were sent during the term of this Agreement from UNIVERSITY to patent counsel relating to the PATENT RIGHTS, with the proviso that such instructions were approved in writing by
LICENSEE. Payments pursuant to this Section 6.2 are not creditable against royalties or any other payment due to UNIVERSITY under this Agreement. 

  
 11 

	6.3	 LICENSEE shall own any new patent application, and any patent that issues therefrom, or new technology in the
SLE FIELD or the MONITORING OF ORGAN TRANSPLANTATION & ORGAN REJECTION FIELD developed independently of the UNIVERSITY and UNIVERSITY employees and shall not owe the UNIVERSITY any fee or royalty under section 4 relating to such a new
patent application, and any patent that issues therefrom, or new technology. 

 ARTICLE 7 – INFRINGEMENT ACTIONS

  

	7.1	 LICENSEE shall inform UNIVERSITY promptly in writing of any alleged infringement of the PATENT RIGHTS by a
third party and of any available evidence thereof. 

  

	7.2	 During the term of this Agreement, LICENSEE shall have the right, but shall not be obligated, to prosecute at
its own expense all infringements of the PATENT RIGHTS in the SLE FIELD or the MONITORING OF ORGAN TRANSPLANTATION & ORGAN REJECTION FIELD and in the TERRITORY if LICENSEE has notified UNIVERSITY in writing of its intent to prosecute;
provided, however, that such right to bring such an infringement action shall remain in effect only for so long as the license granted herein remains exclusive. In furtherance of such right, UNIVERSITY hereby agrees that LICENSEE may include
UNIVERSITY as a party plaintiff in any such suit, without expense to UNIVERSITY. [***]. 

  

	7.3	 If within six (6) months after having been notified of any alleged infringement, LICENSEE shall have been
unsuccessful in persuading the alleged infringer to desist and shall not have brought and shall not be diligently prosecuting an infringement action, or if LICENSEE shall notify UNIVERSITY at any time prior thereto of its intention not to bring suit
against any alleged infringer, then, and in those events only, UNIVERSITY shall have the right, but shall not be obligated, to prosecute at its own expense any 

  

	***	 Certain Confidential Information Omitted 

 
 12 

	 	
infringement of the PATENT RIGHTS, and UNIVERSITY may, for such purposes, use the name of LICENSEE as party plaintiff. [***]. 

 

	7.4	 In the event that a declaratory judgment action alleging invalidity or infringement of any of the PATENT RIGHTS
shall be brought against UNIVERSITY, LICENSEE, at its option, shall have the right, within thirty (30) days after commencement of such action, to intervene and take over the sole defense of the action at its own expense. 

 

	7.5	 In any infringement suit either party may institute to enforce PATENT RIGHTS pursuant to this Agreement, the
other party shall, at the request and expense of the party initiating such suit, cooperate in all respects and, to the extent possible, have its employees testify when requested and make available relevant records, information, samples, specimens,
and other evidence upon request. 

 ARTICLE 8 – INDEMNIFICATION/INSURANCE/LIMITATION OF LIABILITY 

 

	8.1	 LICENSEE shall at all times during the term of this Agreement and thereafter indemnify, defend and hold
UNIVERSITY, its trustees, officers, faculty member, employees and Affiliates (“INDEMNIFIED PARTIES”) harmless against all claims and expenses, including legal expenses and reasonable attorneys’ fees, arising out of the death of or
injury to any person or persons or out of any damage to property or the environment, and against any other claim, proceeding, demand, expense and liability of any kind whatsoever resulting from: (i) the production, manufacture, sale, use,
lease, consumption or advertisement of the LICENSED TECHNOLOGY by Licensee to its sublicensees, (ii) the practice by LICENSEE or any Affiliate or sublicensee of the PATENT RIGHTS; or (iii) arising from or relating to this License
Agreement. LICENSEE shall provide this defense and indemnity whether or not any INDEMNIFIED PARTIES, either jointly or severally, is named as a party defendant and whether or not any INDEMNIFIED PARTIES is alleged to be negligent or otherwise
responsible for any injuries to person or property. The obligation of LICENSEE to defend and indemnify as set forth herein shall 

  

	***	 Certain Confidential Information Omitted 

 
 13 

	 	
survive termination of this Agreement and shall not be limited by any other limitation of liability elsewhere in this Agreement. 

 

	8.2	 LICENSEE shall obtain and carry in full force and effect liability insurance which shall protect LICENSEE and
UNIVERSITY in regard to events covered by Section 8.1 above, as provided below: 

  

					
	 	  	 COVERAGE
	  	 LIMITS

			
	(a)	  	Commercial General Liability, including, but not limited to, Products, Contractual, Fire, Legal and Personal Injury	  	$1,000,000 Combined Single Limits for Bodily Injury and Property Damage
			
	(b)	  	Professional Liability	  	$5,000,000
			
	(c)	  	Products Liability	  	$5,000,000, to be effective on or before the date of first sale of LICENSED TECHNOLOGY products.

 The UNIVERSITY of Pittsburgh is to be named as an additional insured with respect to insurance policies
identified in Sections 8.2(a), 8.2(b), and 8.2(c) above. Certificates of insurance evidencing the coverage required above shall be filed with the UNIVERSITY’S Office of Technology Management, 200 Gardner Steel Conference Center,
Pittsburgh, PA 15260, no later than fifteen (15) days after execution of this Agreement and annually thereafter. Such certificates shall provide that the insurer will give the UNIVERSITY not less than thirty (30) days advance written
notice of any material changes in or cancellation of coverage. 
  

	8.3	 UNIVERSITY, AND ITS AGENTS AND/OR EMPLOYEES, MAKE NO REPRESENTATION AND EXTEND NO WARRANTIES OF ANY KIND,
EITHER EXPRESS OR IMPLIED, INCLUDING BUT NOT LIMITED TO WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, AND VALIDITY OF PATENT RIGHTS CLAIMS, ISSUED OR PENDING. NOTHING IN THIS AGREEMENT SHALL BE CONSTRUED AS A REPRESENTATION OR
WARRANTY THAT THE PRACTICE BY LICENSEE OF THE LICENSE GRANTED HEREUNDER SHALL NOT INFRINGE THE PATENT RIGHTS OF ANY THIRD 

  
 14 

	 	
PARTY. UNIVERSITY ADDITIONALLY DISCLAIMS ALL OBLIGATIONS AND LIABILITIES ON THE PART OF UNIVERSITY, ITS AGENTS AND/OR EMPLOYEES FOR DAMAGES, INCLUDING, BUT NOT LIMITED TO, DIRECT, INDIRECT,
SPECIAL AND CONSEQUENTIAL DAMAGES, ATTORNEYS’ AND EXPERTS’ FEES, AND COURT COSTS (EVEN IF UNIVERSITY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES, FEES OR COSTS), ARISING OUT OF OR IN CONNECTION WITH THIS AGREEMENT, INCLUDING THE
MANUFACTURE, USE OR SALE OF THE PRODUCT(S) AND SERVICE(S) LICENSED UNDER THIS AGREEMENT. LICENSEE ASSUMES ALL RESPONSIBILITY AND LIABILITY FOR LOSS OR DAMAGE CAUSED BY A PRODUCT THAT IS MANUFACTURED, USED OR SOLD BY LICENSEE (INCLUDING SUBLICENSEE
SALES) WHICH IS LICENSED TECHNOLOGY HEREUNDER. 

 ARTICLE 9 – ASSIGNMENT 

Except as expressly provided hereunder, this Agreement is not assignable without the prior written consent of UNIVERSITY which consent shall
not be unreasonably withheld, and any attempt to do so shall be null and void, provided that LICENSEE may assign this Agreement and its rights and obligations thereunder, without the UNIVERSITY’S prior written consent in connection with the
transfer or sale of all or substantially all of the LICENSEE’S business relating to the PATENT RIGHTS and LICENSED TECHNOLOGY to a third party, whether by merger, sale of stock, sale of assets or otherwise subject to LICENSEE providing at least
10 business days written notification to UNIVERSITY and further subject to the assignee agreeing in writing to be bound to all the terms and conditions of this License. The rights and obligations of the parties under this Agreement shall be binding
upon and inure to the benefit of the successors and permitted assigns of the parties. Any assignment not in accordance with this Article 9 shall be null and void. 

ARTICLE 10 – TERM AND TERMINATION 
  

	10.1	 This Agreement shall terminate upon the expiration of the last surviving claim of the PATENT RIGHTS.

  
 15 

	10.2	 UNIVERSITY shall have the right to terminate this Agreement, upon written notice, if: 

 

	 	(a)	 LICENSEE defaults in the performance of any of the obligations herein contained and such default has not been
cured within [***] days after receiving written notice thereof from UNIVERSITY; or 

  

	 	(b)	 LICENSEE ceases to carry out its business, becomes bankrupt or insolvent, applies for or consents to the
appointment of a trustee, receiver or liquidator of its assets or seeks relief under any law for the aid of debtors. 

  

	10.3	 LICENSEE may terminate this Agreement upon six (6) months prior written notice to UNIVERSITY and upon
payment of all amounts accrued or due to UNIVERSITY through the effective date of termination, including patent cost reimbursement pursuant to Article 6 hereof. 

 

	10.4	 Upon termination of this Agreement, neither party shall be released from any obligation that matured prior to
the effective date of such termination. LICENSEE and any sublicensee may, however, after the effective date of such termination, sell all products under the LICENSED TECHNOLOGY which LICENSEE produced prior to the effective date of such termination,
provided that LICENSEE shall pay to UNIVERSITY the royalties thereon as required by Article 4 hereof and submit the reports required by Article 5 hereof. 

ARTICLE 11 – NOTICES 
  

	11.1	 Any notice or communication pursuant to this Agreement shall be sufficiently made or given if sent by certified
or registered mail, postage prepaid, or by overnight courier, with proof of delivery by receipt, addressed to the address below or as either party shall designate by written notice to the other party, or if in accordance with Section 11.3.

  

			
	In the case of University:
		
		 	Associate Vice Chancellor for Technology Management and Commercialization

  

	***	 Certain Confidential Information Omitted 

 
 16 

			
		 	Office of Technology Management
		 	University of Pittsburgh
		 	200 Gardner Steel Conference Center
		 	Thackeray & O’Hara Streets
		 	Pittsburgh, PA 15260
	
	In the case of LICENSEE:
		
		 	Exagen Diagnostics, Inc.
		 	800 Bradbury Drive SE
		 	Suite 108
		 	Albuquerque, NM 87106
		 	Attn: President and CEO

  

	11.2	 Any payments to University hereunder by wire transfer shall be directed as follows: 

 

					
		 	Bank: Mellon Bank, NA, Pittsburgh, PA
		 	ABA Routing No.: 043000261-University of Pittsburgh
		 	Account No.: 0015510
		 	Mellon SWIFT Code: MELNUS3P (international transfers)
		 	Reference Code:	 	 Office of Technology Management, Accountant -

 LICENSEE shall be responsible for all applicable fees and costs relating to any wire transfer, to include
translation fees, without any deduction of such fees from amounts due to the UNIVERSITY pursuant to this Agreement. 
  

	11.3	 All invoices to LICENSEE generated by UNIVERSITY under this Agreement will be sent electronically, via e-mail,
in PDF format, unless instructed otherwise by LICENSEE in writing. 

 ARTICLE 12 – AMENDMENT, MODIFICATION 

This Agreement may not be amended or modified except by the execution of a written instrument signed by the UNIVERSITY’S Executive Vice
Chancellor, or its successor and/or designated UNIVERSITY employee having signatory authority, and LICENSEE’S President. In connection with any agreed upon amendment or modification of this Agreement pursuant to this Article 12, LICENSEE shall
be required to pay an Amendment Fee. 

  
 17 

 ARTICLE 13 – MISCELLANEOUS 

 

	13.1	 This Agreement shall be construed and interpreted in accordance with the laws of the Commonwealth of
Pennsylvania. The forum for any action relating to this Agreement, including those brought against individuals such as UNIVERSITY employees or agents, shall be the Courts of Allegheny County, Pennsylvania, or, if in a federal proceeding, the United
States District Court for the Western District of Pennsylvania. 

  

	13.2	 The parties acknowledge that this Agreement sets forth the entire understanding and intentions of the parties
hereto as to the subject matter hereof and supersedes all previous representations, negotiations, or understandings between the parties and/or its employees or agents, whether written or oral, regarding the subject matter of this Agreement.

  

	13.3	 Nothing contained in this Agreement shall be construed as conferring upon either party any right to use in
advertising, publicity or other promotional activities any name, trade name, trademark, or other designation of the other party, including any contraction, abbreviation, or simulation of any of the foregoing. Without the express written approval of
the other party, neither party shall use any designation of the other party in any promotional activity associated with this Agreement or the LICENSED TECHNOLOGY. Neither party shall issue any press release or make any public statement in regard to
this Agreement without the prior written approval of the other party, except LICENSEE may make such disclosures as are necessary or appropriate to comply with its obligations under applicable laws, rules and regulations of the Securities and
Exchange Commission and securities exchange upon which LICENSEE’S securities are listed. 

  

	13.4	 If one or more of the provisions of this Agreement shall be held invalid, illegal or unenforceable, the
remaining provisions shall not in any way be affected or impaired thereby. In the event any provision is held illegal or unenforceable, the parties shall use reasonable efforts to substitute a valid, legal and enforceable provision which, insofar as
is practical, implements purposes of the provision held invalid, illegal or unenforceable. 

  

	13.5	 Failure at any time to require performance of any of the provisions herein shall not waive or diminish a
party’s right thereafter to demand compliance therewith or with any other 

  
 18 

	 	
provision. Waiver of any default shall not waive any other default. A party shall not be deemed to have waived any rights hereunder unless such waiver is in writing and signed by a duly
authorized officer of the party making such waiver. 

  

	13.6	 LICENSEE acknowledges that UNIVERSITY is free to publish the results of the research activities of its faculty,
staff and students, even though such publication may involve the PATENT RIGHTS or LICENSED TECHNOLOGY. UNIVERSITY agrees to submit to LICENSEE any proposed publication or presentation regarding the subject matter specifically described in the PATENT
RIGHTS for prior review by LICENSEE at least [***] days before its submittal for publication or its presentation. LICENSEE may, within [***] days after receipt of such proposed publication, request that such proposed publication be delayed not more
than [***] days in order to allow for protection of intellectual property rights. 

  

	13.7	 The term “Confidential Information” shall mean any and all proprietary or confidential information of
UNIVERSITY or LICENSEE which may be exchanged between parties at any time and from time to time during the term of this Agreement. Information shall not be considered confidential to the extent that either party can establish by competent proof that
it: (i) is publically disclosed through no fault of any party hereto, either before or after it becomes known to the receiving party; (ii) was known to the receiving party prior to the date of this Agreement, which knowledge was acquired
independently and not from another party hereto (or such party’s employees); (iii) is subsequently disclosed to the receiving party in good faith by a third party who has a right to make such disclosure; or (iv) has been published by
a third party as a matter of right. The parties agree that during the term of this Agreement, and for a period of [***] years after this Agreement terminates, a party receiving Confidential Information of the other party will (a) maintain in
confidence such Confidential Information; (b) not disclose such Confidential Information to any third party and (c) not use such confidential Information for any purpose except those permitted in this Agreement. Notwithstanding the
foregoing, if a party is required by law, regulation or court order to disclose Confidential Information of the other party, the party required to make such disclosure shall limit the same to the minimum required to make such disclosure shall limit
the same to the minimum required 

  

	***	 Certain Confidential Information Omitted 

 
 19 

	 	
to comply with the law or court order, and shall use reasonable efforts to attempt to seek confidential treatment for that disclosure, and prior to making such disclosure that party shall notify
the other party shall notify the other party, not later than ten (10) days (or shorter period of time as may be practicable under the circumstances) before the disclosure in order to allow that other party to comment and/or to obtain protective
or other order, including extensions of time and the like, with respect to such disclosure. In addition, a party may disclose Confidential Information to the other party to employees, to sublicensees and potential sublicensees (in the case of
LICENSEE), or to other third parties in connection with due diligence or similar investigations by third parties or potential third party investors in confidential financing document, provided, in each case, that any such employee, consultant,
agent, sublicense, potential sublicense or other third party agrees in writing to be bound by terms of confidentiality and non-use at least as stringent as those set forth in this Section 13.7. 

 

	13.8	 The parties acknowledge that they consulted, or had the opportunity to investigate and/or consult, with their
legal counsel and/or other advisors with respect to the PATENT RIGHTS, LICENSED TECHNOLOGY, and the terms of this Agreement. 

  

	13.9	 The parties agree that this Agreement constitutes an arm’s length business transaction and does not create
a fiduciary relationship. 

  

	13.10	 LICENSEE agrees that with respect to the performance of this Agreement or the practice of the rights granted by
the UNIVERSITY hereunder, it shall comply with any and all applicable United States export control laws and regulations, as well as any and all embargoes and/or other restrictions imposed by the Treasury Department’s Office of Foreign Asset
Controls. 

  

	13.11	 If LICENSEE challenges the validity or enforceability of UNIVERSITY’S PATENT RIGHTS or UNIVERSITY’S
ownership of the PATENT RIGHTS anywhere in the world, the LICENSEE shall continue to pay to UNIVERSITY all royalties and other financial obligations required under this Agreement, to include patent costs and fees. If any such challenge is
unsuccessful by Licensee, the royalty rates and any non-royalty sublicense income rate set forth in Article 4.1 above shall automatically double in value, 

  
 20 

	 	
to include all royalty minimums and floors; and Licensee shall reimburse the University for all fees and costs associated with defending such action, including but not limited to attorneys fees
and expert fees. The effective date of such increase in royalty rates shall be the date of the first court order or date of issuance of a re-examination certificate (or foreign equivalents thereof) declaring any claim of the PATENT RIGHTS
as valid or enforceable. Within thirty (30) days prior to filing any such challenge, LICENSEE shall provide the UNIVERSITY with written notice of its intent to make such challenge. 

 

	13.12	 Licensee shall mark all Licensed Technology with applicable foreign patent numbers in accordance with the
applicable laws of the countries in which Licensed Technology is used or sold. 

 [remainder of page intentionally left
blank] 

  
 21 

 IN WITNESS WHEREOF, the parties represent and warrant that each has the authority to bind the
party to this Agreement and have set their hands and seals as of the date set forth on the first page hereof. 
  

			
	UNIVERSITY OF PITTSBURGH – OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
		
	By	 	 /s/ Jerome Cochran

		 	Jerome Cochran
		 	Executive Vice Chancellor
	
	EXAGEN DIAGNOSTICS, INC.
		
	By	 	 /s/ Ron Rocca

	Name:	 	Ron Rocca
	Title:	 	C.E.O.

  
 22 

 EXHIBIT A 

PATENT RIGHTS FOR EXCLUSIVE LICENSE AGREEMENT BETWEEN 

THE UNIVERSITY OF PITTSBURGH AND EXAGEN DIAGNOSTICS, INC. 
  

													
	 Univ.

Case

No.
	  	 Application No.
	  	 Application

Filing Date
	  	 Patent No.
	  	 Patent

Issuance

Date
	  	 Title
	  	 Country

	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]

  

	***	 Certain Confidential Information Omitted 

													
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]

  

	***	 Certain Confidential Information Omitted 

 
 24 

													
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]

  

	***	 Certain Confidential Information Omitted 

 
 25 

													
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]

  

	***	 Certain Confidential Information Omitted 

 
 26 

													
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]

  

	***	 Certain Confidential Information Omitted 

 
 27 

													
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]

  

	***	 Certain Confidential Information Omitted 

 
 28 

													
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
							
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]

  

	***	 Certain Confidential Information Omitted 

 
 29 

 EXHIBIT B 

SAMPLE ROYALTY REPORT 
 Licensee name: 

Reporting period: 
 Date of
report: 
 Royalty Reporting Form 
  

																					
	 Product
	  	No. units sold
(including
sublicense)	 	  	Invoiced price
per unit	 	  	Gross sales	 	  	Allowable
deductions	 	  	Net sales	 
	 Product name
	  				  				  				  				  			
	 Product name
	  				  				  				  				  			
	 Product name
	  				  				  				  				  			
	 Product name
	  				  				  				  				  			
		  	  
	  
	 	  	  
	  
	 	  	  
	  
	 	  	  
	  
	 	  	  
	  
	 
	 Total
	  				  				  				  				  			
		  	  
	  
	 	  	  
	  
	 	  	  
	  
	 	  	  
	  
	 	  	  
	  
	 

  

					
	 Total net sales
	  	$	             	 
		  	  
	  
	 
	 Royalty rate
	  			
	 Royalty due
	  	$	             	 

 Total royalty due: $             

Name and addresses of sublicensees: 
 Total non-royalty sublicense
income: $             
 Report prepared by: 

Title: 
 Date: 

  
 30 

 EXHIBIT C 

SAMPLE PROGRESS REPORT 
 Licensee name:

 Report date: 
 Technology title: 

Progress Report 
  

	A.	 Date development plan initiated and time period covered by this report 

 

	B.	 Development report 

  

	 	1.	 Activities, e.g., research and development, regulatory approvals, manufacturing, sublicensing, marketing and
sales, etc., completed since last report including the object and parameters of the development, when initiated, when completed and the results 

  

	 	2.	 Activities currently under investigations, i.e., ongoing activities including object and parameters of such
activities, when initiated, and projected date of completion 

  

	C.	 Future development activities 

 

	 	1.	 Activities to be undertaken before next report including, but not limited to, the type and object of any
studies conducted and their projected starting and completion dates 

  

	 	2.	 Estimated total development time remaining before a product will be commercialized 

 

	D.	 Changes to initial development plan 

 

	 	1.	 Reasons for change 

  

	 	2.	 Variables that may cause additional changes 

 

	E.	 Items to be provided if applicable: 

 

	 	1.	 Information relating to product that has become publicly available, e.g., published articles, competing
products, patents, etc. 

  

	 	2.	 Development work being performed by third parties other than Licensee to include name of third party, reasons
for use of third party, planned future use of third parties including reasons why and type of work 

  

	 	3.	 Update of competitive information trends in industry, government compliance, and market plan

  
 31EX-10.22

 Exhibit 10.22 

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE EXAGEN INC. HAS DETERMINED THE
INFORMATION (I) IS NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO EXAGEN INC. IF PUBLICLY DISCLOSED. 
 EXCLUSIVE LICENSE
AGREEMENT 
 This Agreement (“Agreement”) is made and entered into as of the 5th day of September, 2011 (“EFFECTIVE
DATE”), by and between Thierry DERVIEUX an individual and his company DeNovo, a California limited liability corporation, located at, 240 Coral Rose Irvine, CA 92603 (“DERVIEUX”), and EXAGEN DIAGNOSTICS, INC., a corporation organized
and existing under the laws of Delaware, having an office at 801 University Blvd. SE Suite 103 Albuquerque, NM 87106 (“EXAGEN”). 

WHEREAS, DERVIEUX is the inventor and owner of certain PATENT RIGHTS, as noted in Schedule A, consisting of certain patents and patent
applications, and has the right to grant licenses under such PATENT RIGHTS and has certain DERVIEUX KNOW-HOW; 
 WHEREAS, EXAGEN is
experienced in the development, production, manufacture, marketing and sale of products and/or the use of similar products to the LICENSED TECHNOLOGY and 

WHEREAS, EXAGEN desires to obtain a license under the PATENT RIGHTS AND DERVIEUX KNOW-HOW upon the terms and conditions hereinafter set forth.

 NOW, THEREFORE, in consideration of the premises and the mutual covenants contained herein, the parties hereto, intending to be legally
bound, agree as follows: 
 ARTICLE I - DEFINITIONS 

For purposes of this Agreement, the following words and phrases shall have the following meanings: 

 

	1.1	 “AFFILIATE” shall mean, with respect to either party, any entity that is controlled, operated or
managed by a party, whether or not owned by such party. 

  

	1.2	 “KNOW-HOW” shall mean any and all technical, scientific and other know-how and information, trade
secrets, knowledge, technology, means, methods, processes, practices, formulas, instructions, skills, techniques, procedures, ideas, data, results and other information and materials relating to LICENSED TECHNOLOGY. 

  
 1 

	1.3	 “EXAGEN TECHNOLOGY” shall mean any and all technical, scientific and other know-how and information,
trade secrets, knowledge, technology, means, methods, processes, practices, formulas, instructions, skills, techniques, procedures, ideas, data, results and other information and materials used by EXAGEN to make products. 

 

	1.3	 “FIELD OF USE” shall mean and include LICENSED TECHNOLOGY for use in the human healthcare market.

  

	1.4	 “IMPROVEMENTS” for DERVIEUX shall mean any improvements or enhancements made by either party to
LICENSED TECHNOLOGY. For EXAGEN it shall mean any improvements made to EXAGEN TECHNOLOGY. 

  

	1.5	 “LICENSED TECHNOLOGY” shall be the Patents Rights, Improvements and Know-How described in this
Agreement including the Exhibit A herein. 

  

	1.6	 “PATENT RIGHTS” shall mean the intellectual property described below: 

 

	 	(a)	 Patents and/or patent applications listed in Exhibit A; 

 

	 	(b)	 All patents issued from the applications listed in Exhibit A and from divisionals and continuations and
continuations in part of these applications; and 

  

	 	(c)	 Claims of all continuation in part and divisional applications, and of the resulting patents, which are
directed to subject matter specifically described in applications listed in Exhibit A. 

  

	1.7	 “NET SALES” shall mean the amount collected by EXAGEN or its AFFILIATES to third parties while using
LICENSED TECHNOLOGY and services or testing using the LICENSED TECHNOLOGY and services. Such amount shall be the net amount collected less only: 

  

	 	(a)	 Actual cost of freight, shipping and insurance charges or freight absorption if separately stated in such
invoice; 

  
 2 

	 	(b)	 Actual trade, quantity or cash discounts actually allowed, to include discounts to managed care organizations,
so long as such discounts: (i) are in amounts customary in the trade, and do not violate federal state laws or regulations; 

  

	 	(c)	 Actual credits and allowances granted for rightful product returns and recalls; 

 

	 	(d)	 Rebates paid or credited to managed care organizations and governmental agencies with respect to Medicaid,
Medicare or similar state and federal government programs; 

  

	 	(e)	 Sales taxes, tariff duties and/or use taxes actually paid if separately stated on each invoice; and

  

	 	(f)	 Pass through costs for cost of acquiring the blood sample. 

 

	1.8	 “TERRITORY” shall mean Worldwide except Australia and New Zealand. 

ARTICLE 2 – LICENSE GRANT 
  

	2	 Subject to the terms and conditions of this Agreement, DERVIEUX hereby grants to EXAGEN, the exclusive right
and license to develop, make, have made, use, offer for sale, import and sell the LICENSED TECHNOLOGY in the TERRITORY within the FIELD OF USE and in such connection to practice under DERVIEUX KNOW-HOW and the PATENT RIGHTS until the last patent
expires on a country by country basis, unless this Agreement is terminated as provided herein. 

 ARTICLE 3 - DUE
DILIGENCE 
  

	3.1	 EXAGEN shall use its commercially reasonable efforts to bring the LICENSED TECHNOLOGY to market as soon as
practicable, consistent with sound and reasonable business practice and judgment, and to continue active, diligent efforts for the commercialization of the LICENSED TECHNOLOGY in the TERRITORY throughout the term of this Agreement.

  

	3.2	 Upon execution of this Agreement, DERVIEUX will provide EXAGEN access and support to the following products,
services and other activities: 

  
 3 

	 	(a)	 Assistance with technology transfer. 

 

	 	(b)	 Assistance with the establishment of clinical performances. 

 

	 	(c)	 DERVIEUX will use its commercially reasonable efforts to assist with ongoing clinical validation of the
Licensed Technology. 

  

	 	(d)	 Preparation and compilation of Key scientific publications. 

 

	 	(e)	 Sharing of new clinical data especially on-going clinical activities. 

 

	3.3	 The parties agree to work on new product development using the LICENSED TECHNOLOGY. 

 

	3.4.	 EXAGEN shall own any IMPROVEMENTS made to LICENSED TECHNOLOGY made by EXAGEN or by DERVIEUX while employed by
or is a consultant of EXAGEN, including any IMPROVEMENTS that is a result of the efforts described in section 3.2 and 3.3 above. EXAGEN shall have the option and right to file, prosecute, maintain, defend and enforce any relevant patents, at its
sole expense and in its sole name or the name of its designee. Such IMPROVEMENTS are for the duration of this Agreement to the extent necessary/applicable included under the license grant in section 2. 

 

	3.5	 EXAGEN shall own any IMPROVEMENTS made to all non-LICENSED TECHNOLOGY, including those to EXAGEN TECHNOLOGY and
any IMPROVEMENTS that is a result of the efforts described in section 3.2 and 3.3 above. 

  

	3.6	 EXAGEN’s material failure to perform in accordance with Section 3.1 hereof shall be grounds for
DERVIEUX to terminate this Agreement pursuant to Section 10.3(a); except that through no fault of EXAGEN and following the commercially reasonable efforts of EXAGEN. Upon termination or expiration of this Agreement for any reason (except for
DERVIEUX’S material breach) all rights and interest to the PATENT RIGHTS, DERVIEUX KNOW-HOW AND DERVIEUX IMPROVEMENTS and any other rights granted by DERVIEUX shall revert to DERVIEUX. 

  
 4 

 ARTICLE 4 - LICENSE CONSIDERATION – DELIVERY CONDITIONS 

 

	4.1	 In consideration of the rights, privileges and license granted by DERVIEUX hereunder, EXAGEN shall pay
royalties and other monetary consideration as follows: 

  

	 	(a)	 One time [***] dollars ($[***] US$) upon the issuance of first invoice for sale or use of LICENSED TECHNOLOGY
using PATENT RIGHTS. 

  

	 	(b)	 One time [***] dollars ($[***] US$) upon attaining $[***] in NET SALES in a calendar year using LICENSED
TECHNOLOGY and PATENT RIGHTS. 

  

	 	(c)	 One time [***] dollars ($[***] US$) upon attaining $[***] in NET SALES in a calendar year using LICENSED
TECHNOLOGY and PATENT RIGHTS. 

  

	 	(d)	 Royalty of [***]% of NET SALES for products using or comprising LICENSED TECHNOLOGY, using PATENT RIGHTS. If
LICENSED TECHNOLOGY is used in combination with other technologies not using LICENSED TECHNOLOGY, the Royalties will be calculated using that portion of NET SALES attributable to LICENSED TECHNOLOGY. 

 

	 	(e)	 If such LICENSED TECHNOLOGY is sub licensed to a third party, DERVIEUX shall receive [***]% of all license fees
and royalties attributed to the LICENSED TECHNOLOGY. 

  

	4.2	 In the event that it should prove necessary for EXAGEN to license intellectual property rights owned by a third
party in order to practice the LICENSED TECHNOLOGY in order to avoid infringing the patent or other intellectual property rights of such third party, then EXAGEN shall be entitled to [***]% of a credit of such third party royalties against royalties
due to DERVIEUX under Section 4.1, provided that (i) in no event shall the royalty rate applicable to NET SALES payable to DERVIEUX be less than [***] percent ([***]%). 

  

	***	 Certain Confidential Information Omitted 

 
 5 

	4.3	 All payments pursuant to this Agreement may be made in United States dollars. Payments under
Section 4.1(d) are payable on a country by country basis only in those countries in which there are Patent Rights with respect to the applicable Licensed Technology. 

ARTICLE 5 - REPORTS 
  

	5.1	 Within sixty (60) days after each March 31, June 30, September 30 and
December 31 of each year during the term of this Agreement beginning in the year of the first commercial sale of LICENSED TECHNOLOGY, EXAGEN shall make payment and deliver to DERVIEUX reports of: 

 

	 	(a)	 Total collections for all such products; and 

 

	 	(b)	 Total royalties due. 

 

	5.2	 EXAGEN shall keep full, true and accurate books of account, in accordance with generally accepted accounting
principles, containing all information that may be necessary for the purpose of showing the amounts payable to DERVIEUX hereunder. Such books of account shall be kept at EXAGEN’s principal place of business. Such books and the supporting data
related thereto shall be made available at reasonable times for no more than once a calendar year for three (3) years following the end of the calendar year to which they pertain to the inspection of DERVIEUX or its agents for the purpose of
verifying EXAGEN’S royalty statement or compliance in other respects with this Agreement. The fees and expenses of DERVIEUX’S representatives shall be borne by DERVIEUX; however, if an error of more than [***] percent ([***]%) of the total
payments, then EXAGEN shall bear the fees and expenses of DERVIEUX’S representatives. 

  

	***	 Certain Confidential Information Omitted 

 
 6 

 ARTICLE 6 - PATENT PROSECUTION 

 

	6.1	 EXAGEN with DERVIEUX shall apply for and seek prompt issuance of and maintain during the term of this Agreement
the PATENT RIGHTS in the United States, Australia and other countries it may designate as pertinent in the TERRITORY. EXAGEN shall have the right to determine and manage the legal strategy and prosecute the PATENT RIGHTS. 

 

	6.2	 If EXAGEN decides not to seek patent coverage in any country in the Territory, then DERVIEUX may give a 60 day
notice to EXAGEN that it will seek patent coverage. If EXAGEN does not take action within that time period, DERVIEUX shall have the right to file for such coverage at his own cost. If such patent is issued, all rights for that country would revert
to DERVIEUX. 

  

	6.3	 Except as noted in Section 6.2 all fees and costs including attorneys’ fees relating to the filing,
prosecution and maintenance of the PATENT RIGHTS in the TERRITORY shall be the responsibility of EXAGEN. 

 ARTICLE 7 -
INFRINGEMENT ACTIONS 
  

	7.1	 EXAGEN shall inform DERVIEUX promptly in writing of any alleged infringement of the PATENT RIGHTS by a third
party and of any available evidence thereof. 

  

	7.2	 During the term of this Agreement, EXAGEN shall be responsible, but shall not be obligated, to prosecute at its
own expense all infringements of the PATENT RIGHTS in the TERRITORY. In furtherance of such right, DERVIEUX hereby agrees that EXAGEN may include DERVIEUX as a party plaintiff in any such suit, without expense to DERVIEUX. The total cost of any such
infringement action commenced or defended solely by EXAGEN shall be borne by EXAGEN and EXAGEN shall receive any recovery or damages for past infringement derived therefrom. 

 

	7.3	 If within thirty (30) days after having been notified of any alleged infringement, EXAGEN shall have been
unsuccessful in persuading the alleged infringer to desist and shall not have brought and shall not be diligently prosecuting an infringement action, or if EXAGEN shall notify DERVIEUX at any time prior thereto of its intention not to bring

  
 7 

	 	
suit against any alleged infringer, then, and in those events only, DERVIEUX shall have the right, but shall not be obligated, to prosecute at its own expense any infringement of the PATENT
RIGHTS, and DERVIEUX may, for such purposes, use the name of EXAGEN as party plaintiff. DERVIEUX shall bear all costs and expenses of any such suit. In any settlement or other conclusion, by litigation or otherwise, [***]. 

 

	7.4	 In the event that a declaratory judgment action alleging invalidity or infringement of any of the PATENT RIGHTS
shall be brought against DERVIEUX, at its option, shall have the right, within thirty (30) days after commencement of such action, to intervene and take over the sole defense of the action at its own expense. 

 

	7.5	 In any infringement suit either party may institute to enforce the PATENT RIGHTS pursuant to this Agreement,
the other party shall, at the request and expense of the party initiating such suit, cooperate in all respects and, to the extent possible, have its employees testify when requested and make available relevant records, papers, information, samples,
specimens, and the like. 

 ARTICLE 8 – DERVIEUX WARRANTIES - INDEMNIFICATION - DISCLAIMER/LIMITATION OF LIABILITY

  

	8.1	 DERVIEUX hereby warrants that the Patent filings, delivered to EXAGEN to the best of his knowledge not infringe
any existing or filed patents by himself or a third party and that no other parties have right to the disclosures make within. DERVIEUX makes no representation or warranty that the end products developed by EXAGEN will meet the requirements of
regulatory authorities. 

 EXCEPT AS EXPRESSLY SET FORTH IN THIS AGREEMENT, NEITHER PARTY MAKES A REPRESENTATION OR
WARRANTY OF ANY KIND WHATSOEVER, WHETHER EXPRESS OR IMPLIED 
  

	8.2	 EXAGEN shall at all times during the term of this Agreement and thereafter indemnify, defend and hold DERVIEUX
harmless against all claims and expenses, including legal 

  

	***	 Certain Confidential Information Omitted 

 
 8 

	 	
expenses and reasonable attorneys’ fees, arising out of a) EXAGEN’s activities under this Agreement or b) EXAGEN’s breach of this Agreement. EXAGEN shall provide this defense and
indemnify, the parties are named either jointly or severally, as a party defendant. The obligation of EXAGEN to defend and indemnify as set forth herein shall survive termination of this Agreement and shall not be limited by any other limitation of
liability elsewhere in this Agreement. 

  

	8.3	 DERVIEUX shall at all times during the term of this Agreement and thereafter indemnify, defend and hold EXAGEN
harmless against all claims and expenses, including legal expenses and reasonable attorneys’ fees, arising out of DERVIEUXS breach of warranties made under this Agreement. DERVIEUX shall provide this defense and indemnify, the parties named
either jointly or severally, as a party defendant. The obligation of DERVIEUX to defend and indemnify as set forth herein shall survive termination of this Agreement and shall not be limited by any other limitation of liability elsewhere in this
Agreement. 

 ARTICLE 9 - ASSIGNMENT 
  

	9	 Except as expressly provided hereunder, this Agreement is not assignable without the prior written consent of
the other party which consent shall not be unreasonably withheld, provided that either party may assign this Agreement and its rights and obligations thereunder, without the other party’s prior written consent in connection with the transfer or
sale of all or substantially all of the assignee’s business relating to this agreement to a third party, whether by merger, sale of stock, sale of assets or otherwise subject to the assigning party providing at least 10 business days written
notification to the other party and further subject to the assignee agreeing writing to be bound to all the terms and conditions of this License. The rights and obligations of the parties under this Agreement shall be binding upon and inure to the
benefit of the successors and permitted assigns of the parties. 

  
 9 

 ARTICLE 10 - TERMINATION 

 

	10.1	 This Agreement shall remain in force until terminated by a party pursuant to the provisions below.

  

	10.2	 EXAGEN may terminate this Agreement for convenience upon 12 months written notice. 

 

	10.3	 Either party shall have the right to terminate this Agreement for material breach if: 

 

	 	(a)	 A party shall default in the performance of any of the obligations herein contained and such default has not
been cured within [***] days after receiving written notice thereof; or 

  

	 	(b)	 Either party shall cease to carry out its business, become bankrupt or insolvent, apply for or consent to the
appointment of a trustee, receiver or liquidator of its assets or seek relief under any law for the aid of debtors. 

  

	10.4	 Upon termination of this Agreement, neither party shall be released from any obligation that matured prior to
the effective date of such termination. EXAGEN and any affiliate may, however, for a maximum of six months after the effective date of such termination, sell all products under the LICENSED TECHNOLOGY which EXAGEN produced prior to the effective
date of such termination, provided that EXAGEN shall pay to DERVIEUX the royalties thereon as required by Article 4 hereof. 

ARTICLE 11 – NOTICES 
  

	11	 Any payment, notice or communication pursuant to this Agreement shall be sufficiently made or given if sent by
certified or registered mail, postage prepaid, or by overnight courier, with proof of delivery by receipt, addressed to the address below or as either party shall designate by written notice to the other party. 

  

	***	 Certain Confidential Information Omitted 

 
 10 

			
	In the case of DERVIEUX:	  	In the case of EXAGEN:
		
	Thierry Dervieux	  	EXAGEN Diagnostics, Inc.
	240 Coral Rose	  	801 University Blvd SE
	Irvine, CA 92603	  	Suite 103
		  	Albuquerque, NM 87106
		  	Attn: President

 ARTICLE 12 - AMENDMENT, MODIFICATION 

 

	12	 This Agreement may not be amended or modified except by the execution of a written instrument signed by the
parties hereto. 

 ARTICLE 13 - MISCELLANEOUS 

 

	13.1	 This Agreement shall be construed and interpreted in accordance with the laws of the state of New Mexico. Any
dispute arising out of or in connection with this contract, including any disputes regarding the existence, validity or termination, shall be settled by arbitration arranged by using an arbiter of mutual agreement. 

 

	13.2	 The parties acknowledge that this Agreement sets forth the entire understanding and intentions of the parties
hereto as to the subject matter hereof and all previous understandings between the parties, written or oral, regarding such subject matter. 

  

	13.3	 Nothing contained in this Agreement shall be construed as conferring upon either party any right to use in
advertising, publicity or other promotional activities any name, trade name, trademark, or other designation of the other party, including any contraction, abbreviation, or simulation of any of the foregoing. 

 

	13.4	 If one or more of the provisions of this Agreement shall be held invalid, illegal or unenforceable, the
remaining provisions shall not in any way be affected or impaired thereby. In the event any provision is held illegal or unenforceable, the parties shall use reasonable efforts to substitute a valid, legal and enforceable provision which, insofar as
is practical, implements purposes of the provision held invalid, illegal or unenforceable. 

  
 11 

	13.5	 Failure at any time to require performance of any of the provisions herein shall not waive or diminish a
party’s right thereafter to demand compliance therewith or with any other provision. Waiver of any default shall not waive any other default. A party shall not be deemed to have waived any rights hereunder unless such waiver is in writing and
signed by a duly authorized officer of the party making such waiver. 

  

	13.6	 The parties acknowledge that both parties are free to publish the results of the research and commercial
activities under this Agreement and that the publications may involve the PATENT RIGHTS or LICENSED TECHNOLOGY. DERVIEUX agrees to supply to EXAGEN any proposed publication or presentation regarding the subject matter specifically described in the
PATENT RIGHTS at least [***] days before its submittal for publication or its presentation so it may have ample time to prepare commercial strategies and support material. 

 

	13.7	 The term “Confidential Information” shall mean any and all proprietary or confidential information of
DERVIEUX or EXAGEN which may be exchanged between parties at any time and from time to time during the term of this Agreement. Information shall not be considered confidential to the extent that either party can establish by competent proof that it:
(i) is publically disclosed through no fault of any party hereto, either before or after it becomes known to the receiving party; (ii) was known to the receiving party prior to the date of this Agreement, which knowledge was acquired
independently and not from another party hereto (or such party’s employees); (iii) is subsequently disclosed to the receiving party in good faith by a third party who has a right to make such disclosure; or (iv) has been published by
a third party as a matter of right. The parties agree that during the term of this Agreement, and for a period of five (5) years after this Agreement terminates, a party receiving Confidential Information of the other party will
(a) maintain in confidence such Confidential Information; (b) not disclose such Confidential Information to any third party and (c) not use such confidential Information for any purpose except those permitted in this Agreement.
Notwithstanding the foregoing, if a party is required by law, regulation or court order to disclose Confidential Information of the other party, the party required to make such disclosure shall limit the same to the minimum required to make such
disclosure shall limit the same to the minimum required to comply with the law or court order, and shall use reasonable efforts to attempt to seek confidential treatment for that disclosure, and prior to making such disclosure that party shall
notify the other party shall notify the other party, not later than ten (10) days (or shorter period of time as may be practicable under the circumstances) before the disclosure in order to allow that other party to comment and/or to obtain
protective or other order, including extensions of time and the like, with respect to such disclosure. In addition, a party may disclose Confidential Information to the other party to employees, board members and potential partners, acquirers, or to
other third parties in connection with due diligence or similar investigations by third parties or potential third party investors in confidential financing document, provided, in each case, that any such employee, consultant, agent, sublicense,
potential sublicense or other third party agrees to be bound by terms of confidentiality and non-use. 

 IN WITNESS
WHEREOF, the parties have set their hands and seals as of the date set forth on the first page hereof. 
  

			
	DERVIEUX
		
	By	 	/s/ Thierry Dervieux
	Thierry Dervieux

  

			
	EXAGEN DIAGNOSTICS, INC.
		
	By	 	/s/ Scott L. Glenn
	 Scott L. Glenn

Chairman/CEO

  

	***	 Certain Confidential Information Omitted 

 
 12 

 EXHIBIT A 

PATENT RIGHTS 
  

					
	 Title
	  	 Inventor
	  	 Application No.
Filing Date

	[***]	  	[***]	  	[***]

  

	***	 Certain Confidential Information Omitted 

 
 13

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00299-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00299-of-00352.parquet"}]]